Terms ending in 2028
Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,208,115 | Amino Acid Sequences That Modulate the Interaction Between Cells of the Immune System In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 10,087,251 | Amino Acid Sequences That Modulate the Interaction Between Cells of the Immune System In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 9,475,877 | Amino Acid Sequences Directed Against Rank-L and Polypeptides Comprising the Same for the Treatment of Bone Diseases and Disorders In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 9,534,055 | Amino Acid Sequences Directed Against Rank-L and Polypeptides Comprising the Same for the Treatment of Bone Diseases and Disorders In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 9,969,805 | Amino Acid Sequences Directed Against HER2 and Polypeptides Comprising the Same for the Treatment of Cancers And/Or Tumors In force · High confidence | Ablynx N.V. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.